Sökning: onr:"swepub:oai:DiVA.org:uu-464162" >
Robust humoral and ...
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19
-
- Havervall, Sebastian (författare)
- Karolinska Institutet
-
- Ng, Henry (författare)
- Uppsala universitet,Integrativ Fysiologi,Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Jernbom Falk, August (författare)
- KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
visa fler...
-
- Greilert-Norin, Nina (författare)
- Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Månberg, Anna, 1985- (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Marking, Ulrika (författare)
- Karolinska Institutet
-
- Laurén, Ida (författare)
- Uppsala universitet,Institutionen för farmaci
-
- Gabrielsson, Lena (författare)
- Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Salomonsson, Ann-Christin (författare)
- Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Aguilera, Katherina (författare)
- Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Kihlgren, Martha (författare)
- Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Månsson, Maja (författare)
- Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
-
- Rosell, Axel (författare)
- Karolinska Institutet
-
- Hellström, Cecilia (författare)
- KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Andersson, Eni (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Olofsson, Jennie (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Skoglund, Lovisa (författare)
- Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Yousef, Jamil (författare)
- Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Pin, Elisa (författare)
- KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Lord, Martin (författare)
- Uppsala universitet,Institutionen för farmaci
-
- Åberg, Mikael (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk kemi
-
- Hedhammar, My, Professor, 1975- (författare)
- KTH,Proteinteknologi,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Tegel, Hanna (författare)
- KTH,Proteinvetenskap,Science for Life Laboratory, SciLifeLab,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Dönnes, Pierre (författare)
- SciCross AB, Skövde, Sweden
-
- Phillipson, Mia, 1973- (författare)
- Uppsala universitet,Integrativ Fysiologi
-
- Nilsson, Peter (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Klingström, Jonas (författare)
- Karolinska Institutet
-
- Mangsbo, Sara, 1981- (författare)
- Uppsala universitet,Institutionen för farmaci
-
- Hober, Sophia, Professor, 1965- (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi,Department of Protein Science, SciLifeLab, KTH Royal Institute of Technology, Stockholm, Sweden
-
- Thålin, Charlotte (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2021-09-27
- 2022
- Engelska.
-
Ingår i: Journal of Internal Medicine. - : John Wiley & Sons. - 0954-6820 .- 1365-2796. ; 291:1, s. 72-80
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.ncbi.nlm...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.Methods: We investigated SARS-CoV-2-specific humoral and cellular immune responses more than 8 months post-asymptomatic, mild and severe infection in a cohort of 1884 healthcare workers (HCW) and 51 hospitalized COVID-19 patients. Possible protection against SARS-CoV-2 reinfection was analyzed by a weekly 3-month polymerase chain reaction (PCR) screening of 252 HCW that had seroconverted 7 months prior to start of screening and 48 HCW that had remained seronegative at multiple time points.Results: All COVID-19 patients and 96% (355/370) of HCW who were anti-spike IgG positive at inclusion remained anti-spike IgG positive at the 8-month follow-up. Circulating SARS-CoV-2-specific memory T cell responses were detected in 88% (45/51) of COVID-19 patients and in 63% (233/370) of seropositive HCW. The cumulative incidence of PCR-confirmed SARS-CoV-2 infection was 1% (3/252) among anti-spike IgG positive HCW (0.13 cases per 100 weeks at risk) compared to 23% (11/48) among anti-spike IgG negative HCW (2.78 cases per 100 weeks at risk), resulting in a protective effect of 95.2% (95% CI 81.9%-99.1%).Conclusions: The vast majority of anti-spike IgG positive individuals remain anti-spike IgG positive for at least 8 months regardless of initial COVID-19 disease severity. The presence of anti-spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID-19.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- COVID-19
- SARS-CoV-2
- humoral response
- long-term immunity
- reinfection
- Biotechnology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Havervall, Sebas ...
-
Ng, Henry
-
Jernbom Falk, Au ...
-
Greilert-Norin, ...
-
Månberg, Anna, 1 ...
-
Marking, Ulrika
-
visa fler...
-
Laurén, Ida
-
Gabrielsson, Len ...
-
Salomonsson, Ann ...
-
Aguilera, Kather ...
-
Kihlgren, Martha
-
Månsson, Maja
-
Rosell, Axel
-
Hellström, Cecil ...
-
Andersson, Eni
-
Olofsson, Jennie
-
Skoglund, Lovisa
-
Yousef, Jamil
-
Pin, Elisa
-
Lord, Martin
-
Åberg, Mikael
-
Hedhammar, My, P ...
-
Tegel, Hanna
-
Dönnes, Pierre
-
Phillipson, Mia, ...
-
Nilsson, Peter
-
Klingström, Jona ...
-
Mangsbo, Sara, 1 ...
-
Hober, Sophia, P ...
-
Thålin, Charlott ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
Journal of Inter ...
- Av lärosätet
-
Uppsala universitet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet